Chemical drug therapy of liver cancer

By | April 25, 2012

Chemical drug therapy of liver cancer, primary liver innate expression of multidrug resistance gene (MDR1 gene), is not sensitive to chemotherapy. Systemic treatment of liver cancer are generally not more than 15% efficiency, and the toxicity of large, its value alone has been denied. Local intrahepatic chemotherapy (HAl) increased drug concentration within the liver lesions, a more efficient than systemic chemotherapy, and toxicity is small, but most data show that it does not prolong survival. In recent years, the long-term use of hepatic artery pump reported low-dose treatment of liver cancer, as well as by the portal vein chemotherapy, intraperitoneal chemotherapy for liver cancer to explore, but can delay: survival of cancer patients to be further confirmed. Although chemotherapy alone in the treatment of liver cancer of limited value, but the comprehensive treatment of cancer chemotherapy in two widely used, has a certain role and status. Chemotherapy in the comprehensive treatment of research are the following: 1. Systemic chemotherapy. The therapy can suppress cancer recurrence rates reported are not consistent, which may be the choice of cases, using different methods and so on. 2. Targeted chemotherapy, systemic chemotherapy may be more useful, but its value remains to be further multi-center controlled study to confirm; chemotherapy treatment plus hepatic artery embolization (TAE) of liver cancer by selectively blocking the blood supply to cancer cells necrosis, tumor reduced.Chemical drug therapy of liver cancer, liver chemoembolization (TACE) or by regional chemotherapy combined with embolization to play a double effect, for the treatment of liver cancer is currently the main treatment methods.

Leave a Reply

Your email address will not be published. Required fields are marked *